IL4 and non-Hodgkin lymphoma: In the presence of multiple concentrations of rituximab, CD40L, and IL-4 significantly decreased specific lysis against Ramos (Fig. 2a and b), Raji (Fig. 2c) and SU-DHL-6 (Fig. 2d) NHL cell lines, as well as against primary CLL (Fig. 2e).